PL9643

Peptide

Negativelead readout

Evidence outlook · lead readout

MELODY-1 (NCT05201170) · Dry Eye

The lead readout missed its primary endpoint. The grade and rationale below record what the trial was designed to show and what it found.

MELODY-1 (NCT05201170): The trial was randomized, quadruple-blinded, vehicle-controlled, and large enough to be adequately powered, with hard clinical/objective dry eye measures (corneal staining and ocular pain) as co-primary endpoints -- a strong design overall. However, an outside source indicates that neither co-primary endpoint reached statistical significance, so the study did not demonstrate the treatment effect it was designed to show, which keeps this as a well-designed but inconclusive trial rather than strong positive evidence.

Result from the company press release; the only significant pain result comes from an analysis adjusted after the planned one.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (1)
Dry Eye Disease
Phase 2 (1)
Dry Eye Disease
NCT04268069 · ORA, Inc.
2020-02-14 – 2020-10-05 · Dry Eye Disease
What this study did

Competitive landscape

This drug's own stage for Dry Eye Disease: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
PL9643: this drugPhase 3PeptideMelanocortin receptorsPartial signal
NCT05201170: Co-primary sign endpoint (lissamine green staining) did not achieve statistical significance; in the unadjusted planned analyses neither co-primary reached significance missed
Cyclosporine (Vevye)ApprovedSmall moleculeCalcineurinPartial signalNo reviewed efficacy summary in this indication
ReproxalapPhase 3Small moleculeReactive aldehyde species (RASP)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

No upcoming readouts on record for this asset.

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

28 February 2024Topline resultMELODY-1 Phase 3 misses planned co-primary endpoints
Palatin Technologies · Source ↗